New data indicates bezuclastinib successfully reduces symptoms of SM
A new treatment called bezuclastinib has shown promise in reducing symptoms of non-advanced systemic mastocytosis.
News
-
-
New study examines SM burden from both patient and provider perspectives
A first-of-its-kind study in Europe identified sources of disease burden as reported by patients with SM and their healthcare providers.
-
Reporting of SM and other mast cell disorders is rising, study finds
The use of diagnostic codes for mast cell disorders, such as systemic mastocytosis (SM), appears to be on the rise.
-
New data reveals high emotional impact of indolent systemic mastocytosis
Patients with indolent SM experience significant limitations in their daily lives that directly correlate with symptom burden.
-
Researchers uncover mutation patterns in childhood mastocytosis
The commonly known KIT D816V mutation appeared only in systemic disease, while other KIT mutations were seen in skin-limited cases.
-
New data shows long-term benefits of avapritinib for people living with SM
Updated data shows sustained clinical efficacy and tolerance of Ayvakit (avapritinib) treatment for systemic mastocytosis.
-
Stem cell transplants eradicate SM mutations faster than symptoms
In patients with SM and blood cancer, a stem cell transplant rapidly removed the disease-causing mutation, but tryptase levels took longer.
-
New review examines bone health testing and treatment for patients with SM
Learn about the current challenges and emergent therapies for bone health in patients with indolent SM.
-
Extending venom therapy intervals reduces risk without sacrificing safety
Patients with systemic mastocytosis can safely extend venom immunotherapy (VIT) maintenance intervals to 12 weeks after five years.
-
Patients with SM and multiple cancers have reduced overall survival
Multiple cancers is a risk factor for a poorer prognosis in SM.
Learn more about SM
Sign up for the latest news, perspectives, and information about SM.
